The 2024 cohort of pharmaceutical and biotechnology launches has set a new benchmark, according to analysis by Trinity Life Sciences, with 50% of new launches exceeding their first-year forecasts. Marked by innovative therapies, streamlined regulatory approvals, executional excellence and advanced technology these launches have outperformed prior years across nearly all metrics. 2024 marked a turning point in which commercial execution is on pace with scientific innovation—launches are smarter, faster, and more patient-centric than ever. This whitepaper explores the factors driving these improvements and presents case studies highlighting the strategies and innovations shaping the industry’s future.
Complete the form below to access the white paper.
By clicking "I agree" above, you are agreeing that Trinity will use and protect your personal data in accordance with our Privacy Policy. You can opt out of future marketing communications at any time by clicking the unsubscribe link at the bottom of any marketing email you receive from Trinity.